The study had a relatively low rate of adherence and retention, which is not uncommon in studies of symptomatic conditions. However, a higher incidence of pulmonary embolism, acute kidney injury, and atrial fibrillation was noted in the testosterone group. Of note, a higher incidence of pulmonary embolism, acute kidney injury, and atrial fibrillation was noted in the testosterone group. The primary endpoint occurred in 7% of the testosterone group and in 7.3% of the placebo group. Then, it will be discussed the association of T with the main risks for CVD, namely metabolic syndrome, type 2 diabetes mellitus, obesity, atherosclerosis, dyslipidaemia and hypertension. Cardiovascular diseases (CVD) are one of the leading causes of death worldwide.
However, it should be emphasized that most of these observations are anecdotal or come from small-scale clinical studies, and limited information is available in women. The authors have completed and submitted the Methodist DeBakey Cardiovascular Journal Conflict of Interest Statement and none were reported. Many authors of systematic reviews on the CV risks of TRT call for a large randomized multicenter trial on this issue. Among the subjects with elevated hematocrit, there was only one incident of serious complication (cerebral hemorrhage).34 The most recent meta-analysis examining the adverse effects of TRT was performed by Fernandez-Balsells et al. in 2010. However, none of the individual prostate-related adverse events significantly differed between groups, including incident prostate cancer, which showed no difference between the TRT group and placebo.34 In 2016, Boyle et al. reported results of a meta-analysis on prostate cancer in TRT trials. The TRT group had a significantly greater incidence of all prostate-related adverse events, with a pooled odds ratio of 1.78 (95% CI, 1.07–2.95).
In this study, the testosterone level required to reduce atherosclerotic plaque was found to be near physiological levels.32 This study showed that testosterone inhibited neointimal plaque development at concentrations of 10 and 100 ng/mL. Estradiol treatment in the female rabbits and testosterone treatment in the male rabbits inhibited the buildup of atherosclerotic plaque compared with that in the control groups. Because the male sex is believed to be a risk factor for atherosclerosis, investigation of the relationship between testosterone and atherosclerosis has been explored.30 Bruck et al31 noticed differing results in the literature and thus tested the relationship between testosterone and atherosclerosis in a rabbit model. This suggests that poorly controlled DM may decrease testosterone levels, which suggests that low testosterone levels do not lead to diabetes,28 confirming the previously described study. Experimental rabbits also had decreased testicular and seminal vesicle weight, decreased testosterone levels, and reduced expression of enzymes necessary for testosterone synthesis (StAR, CYP17A1, and 3β‐HSD) compared with controls.
The translational effects of testosterone between in vitro animal and human studies, some of which have conflicting effects, will be discussed in this review. The benefits of testosterone relating to the cardiovascular system are as follows. Compared with normal males, castration and flutamide treatment improved cardiac function after ischemia via upregulation of the protein kinase B (Akt) pathway (a prosurvival, antiapoptosis pathway) in animals with no endogenous testosterone and blocked androgen receptors. Rat hearts from males, females, castrated males, males given flutamide, castrated males given chronic DHT implantation, and castrated males given acute testosterone infusion (ATI) were subjected to 25 minutes of ischemia and 40 minutes of reperfusion in vitro.
Furthermore, there is also the evidence that Tes produces coronary or systemic vasodilation in vivo at physiological concentrations (100 pM to 100 nM) in humans (67) and in canine and porcine animal models (3, 39). In this respect, a significant vasodilation has also been observed at physiological (low nanomolar) concentrations of Tes in rat mesenteric arterioles (64, 68) and human pulmonary resistance arteries (55) in vitro. However, it has been agreed that physiological concentrations of Tes are in the range of 100 pM–100 nM, whereas supraphysiological and pharmacological concentrations exceed 100 nM. The key mechanism underlying Tes-induced vasorelaxation appears to be the modulation of vascular smooth muscle ion channel function, particularly the inactivation of L-type voltage-operated Ca2+ channels and/or the activation of voltage-operated and Ca2+-activated K+ channels. It can damage blood vessels, resulting in internal bleeding inside the muscle during the injection. Their personalized advice can help you attain heart health and optimal hormone balance.